Datta Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 16-12-2024
- Paid Up Capital ₹ 0.20 M
as on 16-12-2024
- Company Age 31 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.12 M
as on 16-12-2024
- Revenue -8.07%
(FY 2020)
- Profit 45.76%
(FY 2020)
- Ebitda 28.38%
(FY 2020)
- Net Worth 15.90%
(FY 2020)
- Total Assets 3.91%
(FY 2020)
About Datta Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M.
The company has closed loans amounting to ₹1.12 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Jyotirmoy Datta, Debasis Datta, and Abhishek Datta serve as directors at the Company.
- CIN/LLPIN
U24232WB1993PTC060186
- Company No.
060186
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Sep 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Datta Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jyotirmoy Datta  | Director | 22-Sep-1993 | Current |
| Debasis Datta | Whole-Time Director | 22-Sep-1993 | Current |
| Abhishek Datta | Director | 22-May-2015 | Current |
Financial Performance of Datta Pharmaceuticals.
Datta Pharmaceuticals Pvt Ltd, for the financial year ended 2020, experienced Minor drop in revenue, with a 8.07% decrease. The company also saw a substantial improvement in profitability, with a 45.76% increase in profit. The company's net worth Soared by an impressive increase of 15.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Datta Pharmaceuticals?
In 2020, Datta Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
K C Datta & Sons Industries Private LimitedActive 25 years 1 monthJyotirmoy Datta is a mutual person
- Recreate Engineering Products Private LimitedActive 9 years 11 months
Jyotirmoy Datta and Abhishek Datta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
I O B Creation Date: 01 Feb 2001 | ₹1.12 M | Satisfied |
How Many Employees Work at Datta Pharmaceuticals?
Unlock and access historical data on people associated with Datta Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Datta Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Datta Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
